Minjia Tan

Research work focuses on protein modification regulation and precision drug intervention based on proteomics technology. The research has discovered new mechanisms of post-translational modifications in epigenetics and cellular metabolism regulation, revealed the importance and universality of targeted intervention of protein modifications in disease treatment, and laid an important foundation for research on mechanisms and new precision treatment strategies for related tumors and metabolic diseases. Has published over 120 SCI papers with more than 13,000 total citations. In the past five years, has published as corresponding author (including co-corresponding) in well-known international academic journals such as Cell (2018, 2020), Cell Metab (2021), Mol Cell (2021, 2022), Nat Chem (2023), Sci Transl Med (2024), Nat Commun (2018, 2024), and J Am Chem Soc (2023). Research work was selected for “Important Medical Progress in China in 2020”. Has received honors including National Science Fund for Distinguished Young Scholars, Chinese Youth Science and Technology Award, National Special Support Plan for Leading Talents in Science and Technology Innovation, Ministry of Science and Technology Leading Talents in Science and Technology Innovation for Young and Middle-aged, National Overseas High-level Youth Talent Program, First Prize of Ministry of Education Natural Science Award for Higher Education Institutions, Shanghai Young Science and Technology Talent (Basic Research Category), WuXi AppTec Life Chemistry Scholar Award, China Stem Cell Innovation Breakthrough Award in Life Medicine, Shanghai Outstanding Academic Leader, Shanghai Branch of Chinese Academy of Sciences Outstanding Young Science and Technology Innovation Talent, Shanghai Pujiang Talent, and Chinese Human Proteome Organization Excellent Young Scholar Award.

1. Liu Z, Liu Y, Qian L, Jiang S, Gai X, Ye S, Chen Y, Wang X, Zhai L, Xu J, Pu C, Li J, He F, Huang M*, and Tan M*. A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies. Mol Cell, 2021, 81: 4076-4090
2. Xu J, Zhang C, Wang X, Zhai L, Ma Y, Mao Y, Qian K, Sun C, Liu Z, Jiang S, Wang M, Feng L, Zhao L, Liu P, Wang B, Zhao X, Xie H, Yang X, Zhao L, Chang Y, Jia J, Wang X, Zhang Y, Wang Y, Yang Y, Wu Z, Yang L, Liu B, Zhao T, Ren S, Sun A, Zhao Y, Ying W, Wang F, Wang G, Zhang Y, Cheng S, Qin J, Qian X, Wang Y, Li J, He F, Xiao T, Tan M*. Integrative proteomic characterization of human lung adenocarcinoma. 2020 Cell 182: 245-261